Marisa Wexler, MS,  senior science writer—

Phage therapy, a promising strategy for treating antibiotic-resistant lung infections that’s currently in clinical trials, can trigger the release of inflammatory signaling molecules from human lung cells, with different types of phages triggering a different set of signaling molecules. That’s according to a study, “Lytic bacteriophages induce…

Treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) helps increase fat stores in adults with cystic fibrosis (CF), especially those who are underweight, a study found. Researchers also found small, though statistically significant, increases in muscle mass in patients who started on Kaftrio. The results showed that Kaftrio mainly affects fat tissues,…

Infections of Pseudomonas aeruginosa usually persist in people with cystic fibrosis (CF) after Trikafta is started, a study reports. The study, “Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis,” was published in mBio. CF is…

A test of physical function called Glittre-ADL may be better than the standard six-minute walk test at identifying physical limitations in people with cystic fibrosis (CF), a study reports. “To our knowledge, this is the first study to evaluate the performance of CF patients on TGlittre and to compare…

Treatment with Trikafta (ivacaftor/tezacaftor/elexacaftor) eases nose and sinus symptoms in eligible patients with cystic fibrosis (CF), and the improvement in nasal symptoms is accompanied by an increase in nasal nitric oxide (nNO), a biomarker. The findings suggest “nNO could be used as an objective, noninvasive outcome measure for…

A five-year study led by scientists at Emory University in Georgia aims to identify new ways to improve quality of life for people with cystic fibrosis (CF). The study, which will be led by Dio Kavalieratos, PhD, director of research at the Emory Palliative Care Center, is funded by…

A novel treatment strategy for cystic fibrosis (CF) that’s based on a cellular structure called the porosome showed promise in cell and animal models of CF caused by the common F508del mutation. In the cell model, this approach was more potent than tezacaftor and ivacaftor, which are CFTR…

Biopharma and biotech companies have launched more than 450 clinical trials into potential new treatments for cystic fibrosis (CF) since 2018, according to a report from Novotech, a contract research organization that specializes in helping drug developers to run trials. “There are ample opportunities presented by advancements in…

The CFTR modulator therapy Kalydeco (ivacaftor) can safely be given to babies with cystic fibrosis (CF) as young as 4 weeks old, according to data from a Phase 3 clinical trial. The findings were the basis of the U.S. Food and Drug Administration (FDA)’s decision to expand…

While Kaftrio — sold as Trikafta in North America — can improve lung function in children with cystic fibrosis (CF), treatment effects are unlikely to be as dramatic in real-world practice as those reported in clinical trials. Rather, for eligible children without substantial lung problems, Kaftrio’s use can…